Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

The Director of the Health Insurance Fund (HSIF), Sasho Klekovski, stated today that he expects that by the end of January all the missing drugs will be available at the University Clinic for ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...

目前，国外已上市的同类产品包括罗氏公司的Ado-trastuzumab emtansine（商品名Kadcyla）和阿斯利康与第一三共合作开发的Fam-trastuzumab deruxtecan（商品名 ...

2025年1月16日，江苏恒瑞医药股份有限公司（证券代码：600276，证券简称：恒瑞医药）宣布，其子公司苏州盛迪亚生物医药有限公司和上海恒瑞医药有限公司收到国家药品监督管理局（国家药监局）核准签发的关于注射用SHR-A1811和注射用SHR-9839的《药物临床试验批准通知书》，并计划于近期开展临床试验。注射用SHR-A1811是一种 ...

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab emtansine) significantly improves overall survival and long-term invasive ...

Ado-trastuzumab emtansine (Kadcyla, Genentech) — often referred to as T-DM1 — also continued to show durable benefit for reducing risk of invasive recurrence or death, long-term results of the ...

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, talks protocol submission formats and how data interoperability can support artificial intelligence. In a recent video interview with ...